Global Glioblastoma Multiforme (GBM) Drugs Market Expected to Reach Nearly $1.4 Billion by 2025

Strategic Insights -

The global glioblastoma multiforme (GBM) drugs market is expected to experience significant growth, driven by a rising geriatric population, increasing incidence cases, and a rich clinical pipeline of new products. GBM is the most common primary malignant form of brain cancer, with an incidence of two to three per 100,000 adults per year, accounting for 52% of all primary brain tumors. The mainstay of treatment for GBMs is surgery, followed by radiation and chemotherapy, but the development of novel approaches to treating glioblastoma remains a great unmet need.

Key Takeaways:

  • The global GBM drugs market is expected to reach nearly $1.4 billion by 2025, expanding at a CAGR of 12.6% during the forecast period.
  • GBM is the most common primary malignant form of brain cancer, with an incidence of two to three per 100,000 adults per year.
  • The mainstay of treatment for GBMs is surgery, followed by radiation and chemotherapy, but the development of novel approaches to treating glioblastoma remains a great unmet need.
  • Nascent Biotech, Inc. (OTCQB: NBIO) is conducting Phase 1 clinical trials for a treatment of Brain Cancer, including GBM, using its monoclonal, antibody, Pritumumab (PTB).
  • Bristol-Myers Squibb Company (NYSE: BMY) has announced the validation of its Marketing Authorization Applications (MAA) for idecabtagene vicleucel (ide-cel) and CC-486.
  • AstraZeneca PLC (NYSE: AZN) has announced the approval of LYNPARZA (olaparib) for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
  • Merck & Co., Inc. (NYSE: MRK) has announced a collaboration agreement with Ridgeback Biotherapeutics LP to develop EIDD-2801, an orally available antiviral candidate for the treatment of patients with COVID-19.
  • Clovis Oncology, Inc. (NASDAQ: CLVS) has announced the approval of Rubraca (rucaparib) for the treatment of adult patients with a deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer (mCRPC).

Statistics:

  • The global GBM drugs market is expected to reach nearly $1.4 billion by 2025, expanding at a CAGR of 12.6% during the forecast period.
  • GBM is the most common primary malignant form of brain cancer, with an incidence of two to three per 100,000 adults per year.
  • The mainstay of treatment for GBMs is surgery, followed by radiation and chemotherapy, but the development of novel approaches to treating glioblastoma remains a great unmet need.
  • The clinical pipeline of new products for GBM includes 15+ active clinical trials.
  • The market size for GBM treatments is expected to increase by 50% by 2025.

Sources:

  • Financial News Media (Financialnewsmedia.com)
  • Nascent Biotech, Inc. (OTCQB: NBIO)
  • Bristol-Myers Squibb Company (NYSE: BMY)
  • AstraZeneca PLC (NYSE: AZN)
  • Merck & Co., Inc. (NYSE: MRK)
  • Clovis Oncology, Inc. (NASDAQ: CLVS)
  • Grand View Research
  • U.S. National Cancer Institute